Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Heikki Joensuu(University of Helsinki), Jorma Isola(Tampere University Hospital), Petri Bono(Helsinki University Hospital), Leena Helle(Kotka Maritime Research Centre), R. Kokko, Jaana Kaleva‐Kerola(Swedish Chemicals Agency), Tapio Utriainen(Helsinki University Hospital), Maija Tarkkanen(Helsinki University Hospital), Vesa Kataja(South Eastern Finland University of Applied Sciences), Seija Ingalsuo(Vaasa Central Hospital), Akseli Hemminki(University of Helsinki), Tapio Salminen(Tampere University Hospital), Tuomo Alanko, Martti Flander(South Karelia Central Hospital), Inkeri Elomaa(Helsinki University Hospital), Sirkku Jyrkkiö(Turku University Hospital), R. Asola(Satakunta Central Hospital), Marjo Pajunen(Central Finland Health Care District), Pirkko‐Liisa Kellokumpu‐Lehtinen, Anna-Stina Jääskeläinen(Helsinki University Hospital), Mika Leinonen, Mervi Rauhala(Kajaani University of Applied Sciences), Kaisu Johansson(Vaasa Central Hospital), Taina Turpeenniemi‐Hujanen(Oulu University Hospital)
Cited by 1,410
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k